<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22375" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Gorlin Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Spiker</surname>
            <given-names>Alison M.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Troxell</surname>
            <given-names>Todd</given-names>
          </name>
          <aff>A.T. Still University; NERMC</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ramsey</surname>
            <given-names>Michael L.</given-names>
          </name>
          <aff>Geisinger Health System</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alison Spiker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Todd Troxell declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael Ramsey declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22375.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Gorlin syndrome, also called Gorlin-Goltz syndrome, basal cell nevus syndrome (BCNS), or nevoid basal cell carcinoma syndrome, is an autosomal dominant familial cancer syndrome. It is characterized by numerous basal cell carcinomas (BCCs), along with skeletal, ophthalmologic, and neurologic abnormalities. Multiple neoplasms arise starting in childhood. This activity reviews the evaluation of patients with Gorlin Syndrome and highlights the role of the interprofessional team in managing this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the genetic basis of Gorlin syndrome.</p></list-item><list-item><p>Outline the pathophysiology of Gorlin syndrome.</p></list-item><list-item><p>Summarize the expected history and physical findings expected in Gorlin syndrome.</p></list-item><list-item><p>Explain the evaluation needed in patients with Gorlin Syndrome and highlight the role of the interprofessional team in managing this condition.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22375&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22375">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22375.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Gorlin syndrome, also called Gorlin-Goltz syndrome, basal cell nevus syndrome (BCNS), or nevoid basal cell carcinoma syndrome, is an autosomal dominant familial cancer syndrome. It is characterized&#x000a0;by numerous basal cell carcinomas (BCCs),&#x000a0;along with skeletal, ophthalmologic, and neurologic&#x000a0;abnormalities. Multiple neoplasms arise starting in childhood.<xref ref-type="bibr" rid="article-22375.r1">[1]</xref><xref ref-type="bibr" rid="article-22375.r2">[2]</xref><xref ref-type="bibr" rid="article-22375.r3">[3]</xref><xref ref-type="bibr" rid="article-22375.r4">[4]</xref></p>
      </sec>
      <sec id="article-22375.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Basal cell nevus syndrome is caused by mutations in the patched (<italic toggle="yes">PTCH</italic>) gene that encodes a transmembrane receptor which recognizes sonic hedgehog signaling proteins. There is near complete penetrance with variable expressivity. De novo mutations represent approximately 20% to 30% of cases of BCNS.</p>
      </sec>
      <sec id="article-22375.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Prevalence of Gorlin syndrome is estimated at 1 per 40,000-60,000. The disease affects&#x000a0;men and women in rather equal distribution (1:1.3). Although the disease affects all races, African American and Asians represent only 5% of cases and more often are incidentally diagnosed with extracutaneous findings, such as odontogenic keratocysts, as compared to BCCs.</p>
      </sec>
      <sec id="article-22375.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Gorlin syndrome is caused by a mutation in patched 1&#x000a0;(<italic toggle="yes">PTCH1</italic>), a tumor suppressor gene located on chromosome 9q.&#x000a0; <italic toggle="yes">PTCH&#x000a0;</italic>encodes a transmembrane receptor protein that recognizes signaling proteins of the sonic hedgehog family. Homozygous inactivation of the <italic toggle="yes">PTCH </italic>gene leads to tumorigenecity and the formation of multiple BCCs and other neoplasms. Patients with Gorlin syndrome inherit one defective copy of the tumor suppressor gene&#x000a0;and acquire a "second hit"&#x000a0;mutation, such as from ultraviolet light or ionizing radiation. Recently, mutations in suppressor of fused gene (<italic toggle="yes">SUFU</italic>) on chromosome 10q and <italic toggle="yes">PTCH2 </italic>on chromosome 1p have been found in patients meeting criteria for Gorlin's syndrome. Of note, patients with <italic toggle="yes">SUFU </italic>mutations have a reported 20-fold increased risk of developing medulloblastoma as compared to <italic toggle="yes">PTCH1 </italic>mutations in Gorlin syndrome.<xref ref-type="bibr" rid="article-22375.r5">[5]</xref><xref ref-type="bibr" rid="article-22375.r6">[6]</xref><xref ref-type="bibr" rid="article-22375.r7">[7]</xref></p>
        <p>Patients with one mutated copy of the&#x000a0;PTCH1&#x000a0;gene in each cell can have the features of&#x000a0;Gorlin syndrome&#x000a0;early in life. This includes skeletal abnormalities and macrocephaly. A&#x000a0;mutation in the second copy of the&#x000a0;PTCH1gene must also occur in certain cells during the person's lifetime for basal cell carcinomas and other tumors to develop. Patients with one&#x000a0;PTCH1&#x000a0;gene mutation eventually develop a second mutation&#x000a0;in some cells and consequently develop various types of tumors.</p>
      </sec>
      <sec id="article-22375.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with Gorlin syndrome can present as early as infancy with&#x000a0;BCCs; however, the median age of developing BCCs is 20 years. Multiple BCCs are the hallmark feature of Gorlin syndrome and BCCs may present as classic translucent papules with telangiectasias or may resemble acrochordons (skin tags). Superficial pits on the palms and soles occur in 75% to 90% of patients. Epidermal inclusion cysts and milia are reported in approximately 50% of cases.</p>
        <p>Pain, swelling, and drainage of jaw cysts (odontogenic keratocysts) may be the initial reason for presentation and occur at an average age of 13 years. Rare reports of malignant transformation of jaw cysts have been reported. Medulloblastoma&#x000a0;is the second most common malignancy in BCNS with a frequency of approximately 5% and occurs at an average age of two years.&#x000a0; Patients may experience&#x000a0;seizures, mental retardation, and other neurologic abnormalities. Musculoskeletal anomalies&#x000a0;are very common occurring in 60% to 75% of patients and often are congenital. Bifid or splayed ribs, frontal bossing, cleft lip/palate, vertebral fusion, pectus excavatum, syndactyly, and hypoplastic thumbs are some potential musculoskeletal anomalies. Ophthalmologic abnormalities such as hypertelorism, congenital blindness, cataracts, strabismus, and colobomas of the retina or iris may occur. Profound bradycardia from cardiac fibromas can occur during general anesthesia.</p>
      </sec>
      <sec id="article-22375.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnosis of BCNS requires the presence of two major or one major and two minor clinical criteria.</p>
        <p>Major criteria include: multiple (&#x0003e;2) BCCs or 1 BCC by &#x02264;20 years of age, odontogenic keratocysts of the jaw proven by histology, palmar or plantar pitting, bilamellar calcification of the falx cerebri, bifid/fused/splayed ribs, first-degree relative with BCNS.</p>
        <p>Minor criteria include:&#x000a0; medulloblastoma, increased circumference of the head, congenital malformations (frontal bossing, coarse facies, cleft lip/palate, moderate or severe hypertelorism), other skeletal abnormalities (Sprengel deformity, marked pectus deformity, marked syndactyly of the digits), radiologic abnormalities (bridging of the sella turcica, hemivertebrae, fusion or elongation of the vertebral bodies, modeling defects of the hands and feet, or flame-shaped lucencies of the hands or feet), ovarian and cardiac fibromas.&#x000a0;</p>
        <p>Genetic testing for <italic toggle="yes">PTCH1 </italic>is suggested for the following situations: (1) diagnosis confirmation in patients lacking sufficient clinical diagnostic criteria; (2) predictive testing for patients at risk with an affected family member but not meeting clinical criteria; (3) prenatal testing if there is a known familial mutation.&#x000a0;</p>
      </sec>
      <sec id="article-22375.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>A multidisciplinary approach is required to manage patients with Gorlin syndrome.&#x000a0; Close surveillance by a dermatologist or dermatologic surgeon&#x000a0;is required to diagnose and treat BCCs as rarely metastasis has occurred in these patients. Pediatric patients should have an annual skin screening by a dermatologist until the first BCC, then undergo screening at least every six months. Adults should have a complete skin check at least every four months.<xref ref-type="bibr" rid="article-22375.r8">[8]</xref><xref ref-type="bibr" rid="article-22375.r9">[9]</xref><xref ref-type="bibr" rid="article-22375.r10">[10]</xref><xref ref-type="bibr" rid="article-22375.r11">[11]</xref></p>
        <p>Numerous baseline examinations are recommended in pediatric patients. Given the risk of medulloblastoma in pediatric patients, a baseline MRI scan of the brain (repeated yearly until eight years of age then discontinue) is recommended. Baseline jaw X-rays as soon as tolerated and repeated annually until first jaw cyst then every six months until no jaw cysts for two years or until the patient is 21 years of age. Baseline spine X-rays at one year of age and repeat if symptomatic or per scoliosis protocol every six months if abnormal. Baseline cardiac ultrasound is recommended in pediatric patients to evaluate for&#x000a0;cardiac fibromas. Girls should have a pelvic ultrasound at menarche or age 18 to evaluate for ovarian fibromas. Annual speech, vision, and hearing screening along with routine developmental screening should be performed in pediatric patients with Gorlin syndrome.</p>
        <p>Patients with Gorlin syndrome not diagnosed in childhood should have a baseline MRI scan of the brain, genetic counseling, and possibly a psychological evaluation if needed. Jaw X-rays should be repeated as needed for symptoms and an annual neurology evaluation should occur&#x000a0;in patients with a history of medulloblastoma. Pregnant patients should undergo a maternal fetal medical evaluation given risk for hydrocephalus, microcephaly, and cardiac fibromas.</p>
        <p>Treatment of BCCs in Gorlin syndrome is challenging given the number of neoplasms.&#x000a0;Electrodessication and curettage, cryosurgery, surgical excision, Mohs micrographic surgery (MMS), and MMS in combination with CO2 laser treatment have all be reported. Topical treatment options include 5% 5-fluorouracil, 5% imiquimod,&#x000a0;or photodynamic therapy. Vismodegib, an antagonist of the smoothened receptor and a hedgehog pathway inhibitor, can be used to treat BCCs in BCNS; however, side effects&#x000a0;can be limiting, and&#x000a0;regrowth of BCCs occurs after cessation of vismodegib.</p>
      </sec>
      <sec id="article-22375.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Bazex syndrome</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Fibrous papule of the face</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Melanocytic nevi</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Milia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pseudohypoparathyroidism</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Rombo syndrome</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Seborrheic keratosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Unilateral nevoid BCC with comedones</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22375.s10" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Increased risk of BCCs is also found in two rare genetic disorders, Bazex-Dupr&#x000e9;-Christol syndrome and Rombo syndrome, which have some phenotypic overlap with Gorlin syndrome.</p>
      </sec>
      <sec id="article-22375.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>an interprofessional approach is required to manage patients with Gorlin syndrome.&#x000a0; Close surveillance by a dermatologist or dermatologic surgeon&#x000a0;is required to diagnose and treat BCCs as rarely metastasis has occurred in these patients. Pediatric patients should have an annual skin screening by a dermatologist until the first BCC, then undergo screening at least every six months. Adults should have a complete skin check at least every four months. Both the primary care provider and nurse practitioner should closely monitor these patients and refer them to a dermatologist if any new skin changes appear. Because of the rarity of the syndrome, there are no large clinical trials on how to best manage these patients.</p>
      </sec>
      <sec id="article-22375.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22375&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22375">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/gorlin-syndrome-gorlin-goltz-syndrome-basal-cell-nevus-syndrome-bcns-or-nevoid-basal-cell-carcinoma-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22375">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22375/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22375">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22375.s13">
        <title>References</title>
        <ref id="article-22375.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hazemann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Michel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mah&#x000e9;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lipsker</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cribier</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>[Histopathological study of basaloid follicular hamartoma].</article-title>
            <source>Ann Dermatol Venereol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>146</volume>
            <issue>3</issue>
            <fpage>181</fpage>
            <page-range>181-191</page-range>
            <pub-id pub-id-type="pmid">30691875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22375.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scalia</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Farulla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fiocchi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Alboni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Torricelli</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Imaging features of uterine and ovarian fibromatosis in Nevoid Basal Cell Carcinoma Syndrome.</article-title>
            <source>J Radiol Case Rep</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>12</volume>
            <issue>9</issue>
            <fpage>21</fpage>
            <page-range>21-30</page-range>
            <pub-id pub-id-type="pmid">30651920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22375.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hasan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Akintola</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>An Update of Gorlin-Goltz Syndrome.</article-title>
            <source>Prim Dent J</source>
            <year>2018</year>
            <month>Sep</month>
            <day>01</day>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>38</fpage>
            <page-range>38-41</page-range>
            <pub-id pub-id-type="pmid">30428966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22375.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gianferante</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Rotunno</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Wyatt</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Mirabello</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Whole-exome sequencing of nevoid basal cell carcinoma syndrome families and review of Human Gene Mutation Database PTCH1 mutation data.</article-title>
            <source>Mol Genet Genomic Med</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>1168</fpage>
            <page-range>1168-1180</page-range>
            <pub-id pub-id-type="pmid">30411536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22375.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shevchenko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Durkin</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>Generalized basaloid follicular hamartoma syndrome versus Gorlin syndrome: A diagnostic challenge.</article-title>
            <source>Pediatr Dermatol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>e396</fpage>
            <page-range>e396-e397</page-range>
            <pub-id pub-id-type="pmid">30152544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22375.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borghesi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nardi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Giannitto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tironi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maroldi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Di Bartolomeo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Preda</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Odontogenic keratocyst: imaging features of a benign lesion with an aggressive behaviour.</article-title>
            <source>Insights Imaging</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>883</fpage>
            <page-range>883-897</page-range>
            <pub-id pub-id-type="pmid">30066143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22375.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sinx</surname>
                <given-names>KAE</given-names>
              </name>
              <name>
                <surname>Roemen</surname>
                <given-names>GMJM</given-names>
              </name>
              <name>
                <surname>van Zutven</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Janssen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Speel</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Steijlen</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>van Geel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mosterd</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Vismodegib-resistant basal cell carcinomas in basal cell nevus syndrome: Clinical approach and genetic analysis.</article-title>
            <source>JAAD Case Rep</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>408</fpage>
            <page-range>408-411</page-range>
            <pub-id pub-id-type="pmid">29984265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22375.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fogel</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Sarin</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>JMC</given-names>
              </name>
            </person-group>
            <article-title>Genetic diseases associated with an increased risk of skin cancer development in childhood.</article-title>
            <source>Curr Opin Pediatr</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>426</fpage>
            <page-range>426-433</page-range>
            <pub-id pub-id-type="pmid">28525403</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22375.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bay</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ousager</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Jelsig</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>[Patients with basal cell naevus syndrome should be offered an early multidisciplinary follow-up and treatment].</article-title>
            <source>Ugeskr Laeger</source>
            <year>2015</year>
            <month>Jul</month>
            <day>13</day>
            <volume>177</volume>
            <issue>29</issue>
            <pub-id pub-id-type="pmid">26239960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22375.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bettoli</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Zauli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Virgili</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Retinoids in the chemoprevention of non-melanoma skin cancers: why, when and how.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>235</fpage>
            <page-range>235-7</page-range>
            <pub-id pub-id-type="pmid">23148804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22375.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dixon</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Managing skin cancer--23 golden rules.</article-title>
            <source>Aust Fam Physician</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>34</volume>
            <issue>8</issue>
            <fpage>669</fpage>
            <page-range>669-71</page-range>
            <pub-id pub-id-type="pmid">16113705</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
